Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S-benzylglutathione is a synthetic tripeptide derivative of glutathione in which the sulfhydryl group of the cysteine residue is substituted with a benzyl group. It belongs to the class of oligopeptides and has been studied primarily as an experimental compound. S-benzylglutathione acts as an analog and inhibitor of glutathione in biochemical assays and has been used to probe isozyme-specific inhibition of glutathione-S-transferase (GST), an enzyme involved in detoxification processes. Its selectivity for different GST isozymes can be modulated by modifications on its aromatic ring, making it useful for studying GST function and specificity[1][3]. There are no approved therapeutic indications or clinical uses for this compound.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on S-benzylglutathione.